Skip to main content
Premium Trial:

Request an Annual Quote

Giuseppe Attardi Dies, Goldberg to Step Down from Genomic Health Board, ProGenTech Appoints Executives, and More

NEW YORK (GenomeWeb News) – California Institute of Technology geneticist Giuseppe Attardi has died at age 84, Caltech reported last week. Born in Italy, Attardi conducted cell research at the Karolinska Institute in Stockholm, Sweden, and he was a Fullbright Fellow at Washington University in St. Louis.
 
At Caltech since 1959, Attardi spent much of his career focused on mitochondria research. His lab at Caltech has focused on how mtDNA replicates, on detecting mutations resulting from aging, and how mtDNA contributes to cellular aging.
 
"He has been a central figure in mitochondrial research for several decades," Attardi’s former colleague David Chan said in a statement.
 
Attardi's widow is a senior research fellow at Caltech and his daughter is a professor of cancer biology at Stanford University.
 

 
The Department of Health and Human Services has appointed Robin Robinson to be the first leader of the newly created Biomedical Advanced Research Development Authority.
 
BARDA operates under the HHS Office of the Assistant Secretary for Preparedness and Response. Robinson currently is deputy director of BARDA’s Influenza and Emerging Disease Program. He will now also be in charge of Project BioShield, which includes procurement and advanced development of medical countermeasures for chemical, biological, radiological, and nuclear agents, as well as development and procurement for pandemic influenza and infectious diseases.
 

 
Michael Goldberg plans to resign from his position on the board of directors of Genomic Health as of the next annual stockholders meeting in May, according to a company filing with the US Securities and Exchange Commission this week.
 

 
Calibrant Biosystems has named Satya Saxena VP of research. Saxena formerly was chief of the Proteomics and Mass Spectrometry Facility at the National Institutes of Health’s National Institute on Aging. Before working with NIH, Saxena was involved in developing New Mexico’s proteomics infrastructure.
 

 
Gene Network Sciences has appointed James Collins, professor of biomedical engineering at Boston University, to the new post of chief scientific officer.
 
The company has also appointed a scientific advisory board. Members include Jeffrey Besterman, executive VP of R&D and CSO of Methylgene; Jeffrey Hanke, VP of cancer care discovery at AstraZeneca; Stuart Kaufmann, chair of biocomplexity and informatics at the University of Calgary; Hiroaki Kitano, who is president of the Institute for Systems Biology; Christophe Lengauer, an executive director at Novartis; Matej Oresic, a principal investigator of systems biology and bioinformatics at VTT Technical Research Center of Finland; and Hans Winkler, senior director of functional genomics at Johnson & Johnson.
 

 
ITI Life Sciences has appointed four new life sciences analysts including Nicolas Peyret, formerly of Applied Biosystems; John Gordon, a former CTO at CalbaTech; Martyn Link, who was a principal analyst for life sciences at Woods Mackenzie of Scotland; and Liz Fletcher, a former life sciences business manager at the University of Southampton.
 

 
ESA Biosciences has hired Michael Pettigrew to be VP of life sciences sales. Pettigrew formerly was VP of North American sales at GE Life Sciences.
 

 
ProGenTech has made several appointments to its senior management team. The company has named Paul Richardson, who formerly headed R&D programs at the US Department of Energy’s Joint Genome Institute, to take over the role of VP of R&D.
 
The company has appointed Jesus Ching to be chief scientist. Ching previously was director of R&D at Cepheid.
 
Sarah Wenning, who was deputy associate director of operations at Lawrence Livermore National Laboratory’s bioscience directorate, has joined the company as VP of US operations.
 
Dylan Bird, a former investor at ProGenTech’s financial backer Bay City Capital, has come into the company as director of business development.
 
David Hu, who was an angel investor and now sits on the company’s board, is stepping into the job of VP of engineering, based in Shanghai.
 

 
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.